Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Advance ZincTek Limited (ANO.AX)
Rocklea, QLD, AU
Founded in 1997 and based in Rocklea, Australia, Advance ZincTek Limited (known as Advance NanoTek Limited until November 2021) is a key supplier to the global personal care sector. The company manufactures various products, including zinc oxide, offered as both powder and dispersions, and aluminum oxide powder. Its specialized offerings encompass mineral-only UV filter dispersions, which are integral to sunscreen, skincare, and pharmaceutical formulations, alongside alumina plate-like powders specifically developed for cosmetic uses. Advance ZincTek operates internationally, reaching markets across Australia, the United States, Canada, Europe, and beyond, facilitated by an extensive network of distributors.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -3.61% | -17.95% | -33.33% | -15.79% | +5.26% | -57.67% | -78.95% | +208.10% | -60.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%+30.5% ★ Q4'25: +19.5% (vs Q4'23)
-
EPS growth Chemicals: +11.7%+236.6% ★ Q4'25: +79.6% (vs Q4'23)
-
FCF margin FCF growth · Chemicals: +41.7%+9.3% ★ Q4'25: +20.2% (vs Q4'23)
-
EBIT margin Chemicals: +7.1%+15.9% ★ Q4'25: +15.2% (vs Q4'23)
-
ROIC Chemicals: +3.4%+3.2% Q4'25: +10.8% (vs Q4'23)
-
Share dilution Chemicals: +0.0%+0.1% Q4'25: +0.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×0.45× ★ Q4'25: 0.16× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 1/5 | 3/5 |
| 2026-05-06 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Geoffrey Brockwell Acton GAICD | MD, Company Secretary & Executive Director | 299.7K | male |
| Geoff Trotter | Manager of Research & Development | 105.6K | — |
| Narelle Lynch | Joint Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ANO.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
